Break it Down: Recce Pharmaceuticals gets Indonesian entry for clinical trial

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Recce Pharmaceuticals’ (ASX:RCE) approval from the Indonesian Government for a phase 3 clinical trial of its topical gel for diabetic foot infections.

The risk of a person with diabetes developing a foot ulcer has been estimated to be as high as 34%  and about half of all diabetic foot ulcers develop infection which can even lead to death.

Tune in to get the latest.

While Recce Pharmaceuticals is a Stockhead advertiser, it did not sponsor this content.